Needham Initiates Coverage On Penumbra with Hold Rating
Needham analyst Mike Matson initiates coverage on Penumbra (NYSE:PEN) with a Hold rating.
Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%
Penumbra Inc (NYSE:PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus…
Penumbra’s Return on Invested Capital Insights
Benzinga Pro data, Penumbra (NYSE:PEN) reported Q4 sales of $204.01 million. Earnings fell to a loss of $24.63 million, resulting in a 406.72% decrease from last quarter. In Q3, Penumbra earned $8.03 million and total sales reached $190.12 million.
Recap: Penumbra Q4 Earnings
Penumbra (NYSE:PEN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Penumbra missed estimated earnings by 54.55%, reporting an EPS of $0.1 versus an estimate of $0.22.
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell
• Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million.
Earnings Outlook For Penumbra
Penumbra (NYSE:PEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-22. Here's what investors need to know before the announcement.
Analysts estimate that Penumbra will report an earnings per share (EPS) of $0.22.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Penumbra Weighing Combination With Shockwave Medical: Bloomberg
Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV),
Penumbra’s Thrombectomy System Shows Safety, Clinical Benefit
Penumbra Inc (NYSE:PEN) announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter met the primary endpoint.…
Penumbra Q3 EPS $0.12 Misses $0.16 Estimate, Sales $190.10M Beat $181.05M Estimate
Penumbra (NYSE:PEN) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.16 by 25 percent. This is a 100 percent increase over earnings of $0.06 per share from the same period